Article Trunk



Chemistry / M2 Pharma, “Novartis passes US FDA approval of Cosentyx for inclusion of new evidence in slowing down joint structural damage in psoriatic arthritis.”

06.20.2018 · Posted in Uncategorized
M2 PHARMA-June 20, 2018-Novartis passes US FDA approval of Cosentyx for inclusion of new evidence in slowing down joint structural damage in psoriatic arthritis (C)2018 M2 COMMUNICATIONS Healthcare company Novartis reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) to include the new evidence that Cosentyx (secukinumab) significantly slows...

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: